194 related articles for article (PubMed ID: 38166689)
1. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.
Lao X; Zhang H; Deng M; Li Q; Xiao Q; He L; Ma L; Song A; Liang X; Yu F; Zhao H; Zhang F
BMC Infect Dis; 2024 Jan; 24(1):8. PubMed ID: 38166689
[TBL] [Abstract][Full Text] [Related]
2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
[TBL] [Abstract][Full Text] [Related]
3. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
Viruses; 2024 May; 16(5):. PubMed ID: 38793602
[TBL] [Abstract][Full Text] [Related]
4. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Hsu JY; Sun HY; Hsieh TW; Chang SY; Chuang YC; Huang YS; Hsiao CY; Su YC; Liu WC; Chang SF; Hung CC
J Glob Antimicrob Resist; 2022 Jun; 29():7-16. PubMed ID: 35172201
[TBL] [Abstract][Full Text] [Related]
5. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
Elvstam O; Malmborn K; Elén S; Marrone G; García F; Zazzi M; Sönnerborg A; Böhm M; Seguin-Devaux C; Björkman P
Clin Infect Dis; 2023 Jan; 76(1):25-31. PubMed ID: 36100984
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
[TBL] [Abstract][Full Text] [Related]
7. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
[TBL] [Abstract][Full Text] [Related]
8. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
[TBL] [Abstract][Full Text] [Related]
9. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
[TBL] [Abstract][Full Text] [Related]
10. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H; Mocroft A; Ryom L; Neesgaard B; Edwards S; Svedhem V; Günthard HF; Zangerle R; Smith C; Castagna A; d'Arminio Monforte A; Wit F; Stecher M; Lehman C; Mussini C; Fontas E; González E; Wasmuth JC; Sönnerborg A; De Wit S; Chkhartishvili N; Stephan C; Petoumenos K; Jaschinski N; Vannappagari V; Gallant J; Young L; Volny Anne A; Greenberg L; Martín-Iguacel R; Poveda E; Llibre JM;
Clin Infect Dis; 2023 Aug; 77(4):593-605. PubMed ID: 37052343
[TBL] [Abstract][Full Text] [Related]
11. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and management of low-level HIV viremia in the era of integrase strand transfer inhibitors.
Shi J; Ying G; Zheng R; Zhang Z
HIV Med; 2024 Mar; 25(3):361-369. PubMed ID: 37990782
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
Ding H; Xu J; Liu J; Wang Q; Kang J; Li X; Zhang Z; Han X; Jiang Y; Geng W; Shang H
HIV Med; 2022 Mar; 23 Suppl 1():64-71. PubMed ID: 35293103
[TBL] [Abstract][Full Text] [Related]
14. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.
Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V;
J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816
[TBL] [Abstract][Full Text] [Related]
15. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.
Fleming J; Mathews WC; Rutstein RM; Aberg J; Somboonwit C; Cheever LW; Berry SA; Gebo KA; Moore RD;
AIDS; 2019 Nov; 33(13):2005-2012. PubMed ID: 31306175
[TBL] [Abstract][Full Text] [Related]
16. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database.
Han WM; Broom J; Bopage R; Templeton DJ; Edmiston N; Petoumenos K;
Trop Med Int Health; 2024 Jan; 29(1):42-56. PubMed ID: 38009461
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
Leierer G; Grabmeier-Pfistershammer K; Steuer A; Geit M; Sarcletti M; Haas B; Kanatschnig M; Rappold M; Zangerle R; Ledergerber B; Taylor N;
PLoS One; 2015; 10(11):e0142923. PubMed ID: 26566025
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
Bai R; Lv S; Hua W; Su B; Wang S; Shao Y; Li Z; Liu A; Sun L; Dai L
HIV Med; 2022 Mar; 23 Suppl 1():72-83. PubMed ID: 35293102
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.
Liu J; Li C; Sun Y; Fu C; Wei S; Zhang X; Ma J; Zhao Q; Huo Y
Sci Rep; 2024 May; 14(1):10620. PubMed ID: 38724547
[TBL] [Abstract][Full Text] [Related]
20. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
